Lexicon Pharmaceuticals, Inc./De - Current report filing (8-K)
February 13 2008 - 4:43PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
__________________
FORM
8-K
__________________
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event
reported): February
7, 2008
Lexicon
Pharmaceuticals, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
|
000-30111
|
76-0474169
|
(State
or other jurisdiction of
incorporation
or organization)
|
(Commission
File Number)
|
(I.R.S.
Employer
Identification
Number)
|
8800
Technology Forest Place
The
Woodlands, Texas 77381
(Address
of principal executive
offices
and Zip Code)
(281)
863-3000
(Registrant’s
telephone number,
including
area code)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligations of the registrant under any of the following
provisions:
□
|
Written
communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
|
□
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
□
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))
|
□
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c))
|
Item
5.02
|
Departure
of Directors or Certain Officers; Election of Directors; Appointment of
Certain Officers; Compensatory Arrangements of Certain
Officers
|
(e) On
January 7, 2008, the Compensation Committee of our Board of Directors approved
2008 base salaries and a process for the determination of 2008 cash bonuses for
our named executive officers. The 2008 salary information and a
description of the 2008 cash bonus determination process is attached to this
current report on Form 8-K as Exhibit 10.1 and incorporated herein by
reference.
The
Compensation Committee also approved the grant of stock options to our named
executive officers under our 2000 Equity Incentive Plan. The form of
stock option agreement applicable to such stock options is attached to this
current report on Form 8-K as Exhibit 10.2 and incorporated herein by
reference.
The
Compensation Committee also approved the payment of 2007 cash bonuses to our
named executive officers as described below:
Name and Position
|
|
2007
Cash Bonus
|
|
Arthur
T. Sands, M.D., Ph.D.
President
and Chief Executive Officer
|
|
$
|
265,000
|
|
Julia
P. Gregory
Executive
Vice President and Chief Financial Officer
|
|
$
|
120,000
|
|
Alan
J. Main, Ph.D.
Executive
Vice President of Pharmaceutical Research
|
|
$
|
130,000
|
|
Jeffrey
L. Wade, J.D.
Executive
Vice President and General Counsel
|
|
$
|
130,000
|
|
Brian
P. Zambrowicz, Ph.D.
Executive
Vice President and Chief Scientific Officer
|
|
$
|
140,000
|
|
Item
9.01
|
Financial Statements and
Exhibits
|
(d) Exhibits
Exhibit No.
|
Description
|
10.1
|
—
|
Summary
of 2008 Named Executive Officer Cash Compensation
|
10.2
|
—
|
Form
of Stock Option Agreement with Officers under the 2000 Equity Incentive
Plan
|
Signatures
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
|
Lexicon
Pharmaceuticals, Inc.
|
|
|
|
|
|
|
Date: February
13, 2008
|
By:
|
/s/
Jeffrey L. Wade
|
|
|
Jeffrey
L. Wade
|
|
|
Executive Vice
President
and
|
|
|
General
Counsel
|
Index
to Exhibits
Exhibit No.
|
Description
|
10.1
|
—
|
Summary
of 2008 Named Executive Officer Cash Compensation
|
10.2
|
—
|
Form
of Stock Option Agreement with Officers under the 2000 Equity Incentive
Plan
|
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Jul 2023 to Jul 2024